This inventor holds 3 USPTO granted patents. Top assignees: Genematrix Inc., Eyegene Inc.. Active years: 2007-2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Gyeonggi-do, KR (2007 - 2009)
- Seoul, KR (2011)
Company Filing History:
Years Active: 2007-2011
Title: Wang-Don Yoo: Innovator in Genetic Diagnostics
Introduction
Wang-Don Yoo is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of genetic diagnostics, holding a total of 3 patents. His work focuses on innovative methods for diagnosing and detecting genetic conditions, particularly in relation to diabetic retinopathy.
Latest Patents
Wang-Don Yoo's latest patents include a method for diagnosing diabetic retinopathy by single nucleotide polymorphism, which utilizes the genetic variations of VEGF and its receptor. Additionally, he has developed a method for detecting base mutations, aimed at providing precise and effective techniques for identifying mutations in organisms.
Career Highlights
Throughout his career, Wang-Don Yoo has worked with notable companies such as Genematrix Inc. and Eyegene Inc. His experience in these organizations has allowed him to advance his research and contribute to the development of cutting-edge diagnostic tools.
Collaborations
Wang-Don Yoo has collaborated with esteemed colleagues, including Suk-Joon Kim and Soo-Ok Kim. These partnerships have fostered a collaborative environment that enhances innovation and research in genetic diagnostics.
Conclusion
Wang-Don Yoo's contributions to the field of genetic diagnostics are noteworthy, as he continues to push the boundaries of innovation through his patents and collaborations. His work has the potential to significantly impact the diagnosis and treatment of genetic conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile